Press Releases Year None202120202019201820172016 Nov 22, 2021 Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease Nov 16, 2021 Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia Nov 09, 2021 Imara Reports Third Quarter 2021 Financial Results and Business Highlights Nov 08, 2021 Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) Nov 04, 2021 Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights Nov 04, 2021 Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021 Sep 15, 2021 Imara to Participate in Upcoming Investor Conferences Sep 03, 2021 Imara to Present at Upcoming Investor Conferences Aug 06, 2021 Imara Reports Second Quarter 2021 Financial Results and Business Highlights Aug 05, 2021 Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 26
Press Releases Year None202120202019201820172016 Nov 22, 2021 Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease Nov 16, 2021 Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia Nov 09, 2021 Imara Reports Third Quarter 2021 Financial Results and Business Highlights Nov 08, 2021 Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) Nov 04, 2021 Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights Nov 04, 2021 Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021 Sep 15, 2021 Imara to Participate in Upcoming Investor Conferences Sep 03, 2021 Imara to Present at Upcoming Investor Conferences Aug 06, 2021 Imara Reports Second Quarter 2021 Financial Results and Business Highlights Aug 05, 2021 Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 26
Nov 22, 2021 Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease
Nov 16, 2021 Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia
Nov 08, 2021 Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
Nov 04, 2021 Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights
Nov 04, 2021 Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
Aug 05, 2021 Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
